Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, 825 Eastlake Ave, E., G3-630, Seattle, WA 98109, USA.
Breast Cancer Res Treat. 2011 Jan;125(1):169-73. doi: 10.1007/s10549-010-0923-y. Epub 2010 May 11.
This analysis addresses risk of breast cancer among women in BRCA-positive families who test negative for the family mutation. We compared the number of prospectively diagnosed breast cancers in 395 mutation-negative women from 28 BRCA1/2-positive families to an age-, race-, and calendar time-specific expected number of breast cancers derived from the SEER 9 Cancer Registry. Study participants contributed a total of 7008.1 person-years of follow-up. The mean age at study entry was 31.3 years; mean follow-up was 17.7 years. Ten women developed breast cancer yielding an observed-to-expected ratio of 0.82 (95% CI 0.39-1.51). Adjustment for possible reduction in breast cancer risk due to oophorectomy by two different methods resulted in O/E ratios in the range of 0.80-0.99. Stratification by degree of relatedness to the nearest mutation carrier did not substantially alter these results, however, women with at least one-first degree relative with breast cancer appeared to have a slightly increased, though not statistically significant, risk of breast cancer (O/E ratio = 1.33, 95% CI 0.41-2.91). Our data suggest that breast cancer risk among mutation-negative women from BRCA1/2 mutation-positive families is similar to that observed in the general population, with a possible slight increase in risk among mutation-negative women with a family history of breast cancer in a first degree relative. Although this is the largest prospective cohort yet assembled to address this important question, the number of breast cancer events is still relatively small.
本分析针对 BRCA 阳性家族中检测为家族突变阴性的女性的乳腺癌风险。我们将 28 个 BRCA1/2 阳性家族中 395 名突变阴性女性的前瞻性诊断乳腺癌数量与 SEER9 癌症登记处得出的特定年龄、种族和日历时间的预期乳腺癌数量进行了比较。研究参与者共提供了 7008.1 人年的随访。研究入组时的平均年龄为 31.3 岁;平均随访时间为 17.7 年。10 名女性患上了乳腺癌,观察到的与预期的比值为 0.82(95%CI 0.39-1.51)。通过两种不同方法调整因卵巢切除术而可能降低乳腺癌风险,得到的 O/E 比值在 0.80-0.99 之间。按与最近的突变携带者的亲缘关系程度进行分层,并未显著改变这些结果,然而,至少有一名一级亲属患有乳腺癌的女性似乎有略微增加的乳腺癌风险(尽管无统计学意义)(O/E 比值=1.33,95%CI 0.41-2.91)。我们的数据表明,BRCA1/2 突变阳性家族中突变阴性女性的乳腺癌风险与一般人群相似,具有一级亲属乳腺癌家族史的突变阴性女性的风险可能略有增加。尽管这是迄今为止最大的前瞻性队列,用于解决这个重要问题,但乳腺癌事件的数量仍然相对较少。
Breast Cancer Res Treat. 2010-5-11
Breast Cancer Res Treat. 2010-1
Breast Cancer Res Treat. 2019-2-12
Breast Cancer Res Treat. 2011-11-24
J Natl Cancer Inst. 2010-11-23
Breast Cancer Res Treat. 2010-1
CA Cancer J Clin. 2009
Eur J Surg Oncol. 2006-12